This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why it is Worth Investing in Barnes (B) Stock Now
by Zacks Equity Research
Barnes' (B) solid segmental business, margin expansion, acquisitions and shareholder-friendly policies appear promising.
Here's Why You Should Avoid RBC Bearings (ROLL) Stock Now
by Zacks Equity Research
RBC Bearings (ROLL) is likely to suffer from rising cost of sales and high selling, general and administrative expenses as well as supply-chain constraints in the aerospace market.
Create a Value-Based Portfolio With These 5 Low P/CF Stocks
by Zacks Equity Research
One of the important factors that make P/CF a highly dependable metric is that operating cash flow adds back non-cash charges.
Zacks Value Trader Highlights: Apple, NVIDIA, Colfax, Greenbrier and KBR
by Zacks Equity Research
Zacks Value Trader Highlights: Apple, NVIDIA, Colfax, Greenbrier and KBR
Here's Why it is Worth Investing in Brady (BRC) Stock Now
by Zacks Equity Research
Brady (BRC) to gain from robust organic growth in segments, product innovation and initiatives to drive operational excellence.
Nordson (NDSN) Rolls Out Dispending Videos for Manufacturers
by Zacks Equity Research
Nordson (NDSN) launches four informative videos for improving the dispending process of fluid dispending system manufacturers.
Top Ranked Value Stocks to Buy for January 4th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, January 4th
How to Use the Zacks Rank to Find Great Value Stocks
by Tracey Ryniec
Is the Zacks Rank right for you? Find out its strengths, and weaknesses, in screening for stocks.
Kadant (KAI) Buys Syntron Material Handling for $179M in Cash
by Zacks Equity Research
Kadant's (KAI) Syntron Material Handling buyout to expand its growth opportunities in process industries.
Here's Why You Should Avoid Betting on Roper (ROP) Stock Now
by Zacks Equity Research
Roper (ROP) might suffer from high costs and operating expenses, increase in tax rate for the fourth quarter, huge debt levels, and integration woes.
Should Value Investors Buy Colfax (CFX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks.com featured highlights include: Colfax, Domtar, World Fuel Services, Capital One Financial and Escalade
by Zacks Equity Research
Zacks.com featured highlights include: Colfax, Domtar, World Fuel Services, Capital One Financial and Escalade
7 Low Price-to-Sales Stocks to Invest in for Solid Returns
by Zacks Equity Research
A stock with a price-to-sales below 1 is a good bargain, as investors need to pay less than a dollar for a dollar's worth.
Here's Why it is Worth Investing in Colfax (CFX) Stock Now
by Zacks Equity Research
Colfax (CFX) to gain from strengthening end markets, productivity initiatives, pricing actions and lower taxes. Also, acquisitions, including the DJO Global buyout after completion, will aid.
CFX vs. GTLS: Which Stock Is the Better Value Option?
by Zacks Equity Research
CFX vs. GTLS: Which Stock Is the Better Value Option?
Colfax (CFX) Provides Financial Projections for 4Q18 and 2019
by Zacks Equity Research
Colfax (CFX) benefits from healthy segmental business, acquisitions and restructuring moves. It provides segmental projections for 2019 and briefs on estimates for the fourth quarter and 2018.
Colfax Secures $3B Bank Financing to Fund DJO Global Buyout
by Zacks Equity Research
Colfax (CFX) raises roughly $3 billion through bank financing from the group of 23 banks, which will fund the company's acquisition of DJO Global.
Colfax (CFX) Gains From Buyouts, High Costs Remain a Drag
by Zacks Equity Research
Colfax (CFX) benefits from solid business opportunities created by acquired assets. DJO Global, after acquisition, will mark Colfax's entry to the orthopedic market. However, high costs remain a drag.
Company News For Nov 20, 2018
by Zacks Equity Research
Companies In The News Are: XEC,REN,SPB,WBA,CFX
Colfax to Enter Medical Solutions Market With DJO Global Deal
by Zacks Equity Research
Colfax's (CFX) entry into the medical solutions industry, with the DJO Global buyout, will boost its earnings in the near term and strengthen its growth opportunities in the long run.
Colfax's (CFX) Q3 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Colfax's (CFX) Q3 adjusted earnings beat estimates, however revenues miss the mark.
Colfax (CFX) Tops Q3 Earnings Estimates
by Zacks Equity Research
Colfax (CFX) delivered earnings and revenue surprises of 3.85% and -2.02%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Colfax (CFX) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Must Hold on to Colfax (CFX) Stock Now
by Zacks Equity Research
Colfax (CFX) gains from solid business opportunities in its segments and acquisitions as well as geographical expansion. However, high debts, rise in costs and unfavorable orders might be concerning.
Zacks.com highlights: Colfax, United Therapeutics, Trinseo, Xilinx and Archer Daniels Midland
by Zacks Equity Research
Zacks.com highlights: Colfax, United Therapeutics, Trinseo, Xilinx and Archer Daniels Midland